WG
ATXS

Winton Group’s Astria Therapeutics ATXS Stock Holding History

Winton Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,374
Closed -$274K – 1320
2020
Q3 		$274K Sell
7,374
-2,629
-26% -$104K 0.01% 1274
2020
Q2 		$386K Buy
10,003
+1,868
+23% +$66.5K 0.01% 1237
2020
Q1 		$203K Sell
8,135
-1,196
-13% -$37.1K 0.01% 1252
2019
Q4 		$331K Sell
9,331
-1,562
-14% -$49.2K ﹤0.01% 1344
2019
Q3 		$353K Buy
+10,893
New +$431K ﹤0.01% 1213

Other funds holding ATXS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Winton Group's ATXS Position: Q4 2020 in Review

Winton Group sold out of Astria Therapeutics (ATXS) in Q4 2020, closing a stake of 7,374 shares — an estimated $274K sold.

Winton Group first reported a position in ATXS in Q3 2019 and held it in 5 quarters. The position peaked at $386K in Q2 2020. 62 funds tracked by Wall St. Rank hold ATXS as of Q4 2020.

  • Winton Group reported no remaining Astria Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 7,374 Astria Therapeutics shares in Q4 2020, an estimated $274K.
  • Winton Group first reported a position in Astria Therapeutics in Q3 2019 and held it in 5 quarters.
  • Winton Group's Astria Therapeutics position peaked at $386K in Q2 2020.
  • 62 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.